CD4-dependent characteristics of coreceptor use and HIV type 1 V3 sequence in a large population of therapy-naive individuals

AIDS Research and Human Retroviruses

Volumn 24, Issue 2, 2008, Pages 219-228

  Low, Andrew J ^a,b   Marchant, David ^b   Brumme, Chanson J ^a   Brumme, Zabrina L ^a   Dong, Winnie ^a   Sing, Tobias ^c   Hogg, Robert S ^a   Montaner, Julio S G ^a,b   Gill, Vikram ^a,b   Cheung, Peter K ^a   Harrigan, P Richard ^a,b,d  

^a ST PAUL S HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c MAX PLANCK INSTITUTE FOR INFORMATICS   (Germany)

^d BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; PHENOTYPE; PRIORITY JOURNAL;

BRITISH COLUMBIA; CD4 LYMPHOCYTE COUNT; CROSS-SECTIONAL STUDIES; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; PEPTIDE FRAGMENTS; RECEPTORS, CCR5; RECEPTORS, CXCR4; VIRAL LOAD; VIRUS ATTACHMENT;

EID: 39549094435     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2007.0140     Document Type: Article

References (50)

1. Alkhatib G, Combadiere C, Broder CC, et al.: CC CKR5: A RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 1996;272(5270):1955-1958.
2. Deng H, Liu R, Ellmeier W, et al.: Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996;381(6584):661-666.
3. Berger EA, Doms RW, Fenyo EM, et al.: A new classification for HIV-1. Nature 1998;391(6664):240.
4. Dragic T, Litwin V, Allaway GP, et al.: HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996;381(6584):667-673.
5. Feng Y, Broder CC, Kennedy PE, and Berger EA: HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996;272(5263):872-877.
6. Schuitemaker H, Kootstra NA, de Goede RE, de Wolf F, Miedema F, and Tersmette M: Monocytotropic human immunodeficiency virus type 1 (HIV-1) variants detectable in all stages of HIV-1 infection lack T-cell line tropism and syncytium-inducing ability in primary T-cell culture. J Virol 1991;65(1):356-363.
7. Connor RI and Ho DD: Human immunodeficiency virus type 1 variants with increased replicative capacity develop during the asymptomatic stage before disease progression. J Virol 1994;68(7):4400-4408.
8. Berger EA, Murphy PM, and Farber JM: Chemokine receptors as HIV-1 coreceptors: Roles in viral entry, tropism, and disease. Annu Rev Immunol 1999;17:657-700.
9. Glushakova S, Yi Y, Grivel JC, et al.: Preferential coreceptor utilization and cytopathicity by dual-tropic HIV-1 in human lymphoid tissue ex vivo. J Clin Invest 1999;104(5):R7-R11.
10. Tersmette M, Gruters RA, de Wolf F, et al.: Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: Studies on sequential HIV isolates. J Virol 1989;63(5):2118-2125.
11. Schuitemaker H, Koot M, Kootstra NA, et al.: Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: Progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population. J Virol 1992;66(3):1354-1360.
12. Koot M, Keet IP, Vos AH, et al.: Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann Intern Med 1993;118(9):681-688.
13. Richman DD and Bozzette SA: The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression. J Infect Dis 1994;169(5):968-974.
14. Shaheen F and Collman RG: Co-receptor antagonists as HIV-1 entry inhibitors. Curr Opin Infect Dis 2004;17(1):7-16.
15. Dong XN, Chen X, Chen Y, et al.: HIV type 1 phenotype, tropism, and sequence patterns: Association and preference. AIDS Res Hum Retroviruses 2005;21(3):234-238.
16. Trouplin V, Salvatori F, Cappello F, et al.: Determination of coreceptor usage of human immunodeficiency virus type 1 from patient plasma samples by using a recombinant phenotypic assay. J Virol 2001;75(1):251-259.
17. Whitcomb JM, Huang W, Fransen S, et al.: Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob Agents Chemother 2007;51(2):566-575.
18. De Jong JJ, De Ronde A, Keulen W, Tersmette M, and Goudsmit J: Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: Analysis by single amino acid substitution. J Virol 1992;66(11):6777-6780.
19. Fouchier RA, Groenink M, Kootstra NA, et al.: Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. J Virol 1992;66(5):3183-3187.
20. Malenbaum SE, Yang D, Cavacini L, Posner M, Robinson J, and Cheng-Mayer C: The N-terminal V3 loop glycan modulates the interaction of clade A and B human immunodeficiency virus type 1 envelopes with CD4 and chemokine receptors. J Virol 2000;74(23):11008-11016.
21. Troyer RM, Collins KR, Abraha A, et al.: Changes in human immunodeficiency virus type 1 fitness and genetic diversity during disease progression. J Virol 2005;79(14):9006-9018.
22. Pillai S, Good B, Richman D, and Corbeil J: A new perspective on V3 phenotype prediction. AIDS Res Hum Retroviruses 2003;19(2):145-149.
23. Sing T, Harrigan R, Beerenwinkel N, et al.: Immunologic markers improve genotypic prediction of HIV-1 co-receptor usage. Int Workshop Target HIV Entry 2005;1:30.
24. Resch W, Hoffman N, and Swanstrom R: Improved success of phenotype prediction of the human immunodeficiency virus type 1 from envelope variable loop 3 sequence using neural networks. Virology 2001;288(1):51-62.
25. Jensen MA and van 't Wout AB: Predicting HIV-1 coreceptor usage with sequence analysis. AIDS Rev 2003;5(2):104-112.
26. Brumme ZL, Dong WW, Yip B, et al.: Clinical and immunological impact of HIV envelope V3 sequence variation after starting initial triple antiretroviral therapy. AIDS 2004;18(4):F1-9.
27. Brumme ZL, Goodrich J, Mayer HB, et al.: Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals. J Infect Dis 2005;192(3):466-474.
28. Wood E, Montaner JS, Tyndall MW, Schechter MT, O'Shaughnessy MV, and Hogg RS: Prevalence and correlates of untreated human immunodeficiency virus type 1 infection among persons who have died in the era of modern antiretroviral therapy. J Infect Dis 2003;188(8):1164-1170.
29. Hogg RS, Yip B, Chan KJ, et al.: Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA 2001;286(20):2568-2577.
30. Edgar RC: MUSCLE: Multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res 2004;32(5):1792-1797.
31. Pollakis G, Kang S, Kliphuis A, Chalaby MI, Goudsmit J, and Paxton WA: N-linked glycosylation of the HIV type-1 gp120 envelope glycoprotein as a major determinant of CCR5 and CXCR4 coreceptor utilization. J Biol Chem 2001;276(16):13433-13441.
32. Petropoulos CJ, Parkin NT, Limoli KL, et al.: A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother 2000;44(4):920-928.
33. Deeks SG, Wrin T, Liegler T, et al.: Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med 2001;344(7):472-480.
34. Bozzette SA, McCutchan JA, Spector SA, Wright B, and Richman DD: A cross-sectional comparison of persons with syncytium- and non-syncytium-inducing human immunodeficiency virus. J Infect Dis 1993;168(6):1374-1379.
35. Furrer H, Wendland T, Minder C, et al.: Association of syncytium-inducing phenotype of HIV-1 with CD4 cell count, viral load and sociodemographic characteristics. AIDS 1998;12(11):1341-1346.
36. Moyle GJ, Wildfire A, Mandalia S, et al.: Prevalence and predictive factors for CCR5 and CXCR4 co-receptor usage in a large cohort of HIV positive individuals. Int Conf Antimicrob Agents Chemother (ICAAC) 2004;44:H-1135.
37. Demarest J, Bonny T, Vavro C, et al.: HIV-1 co-receptor tropism in treatment naive and experienced subjects. Int Conf Antimicrob Agents Chemother (ICAAC) 2004;44:H-1136.
38. Scoggins RM, Taylor JR Jr, Patrie J, van't Wout AB, Schuitemaker H, and Camerini D: Pathogenesis of primary R5 human immunodeficiency virus type 1 clones in SCID-hu mice. J Virol 2000;74(7):3205-3216.
39. van't Wout AB, Ran LJ, Kuiken CL, Kootstra NA, Pals ST, and Schuitemaker H: Analysis of the temporal relationship between human immunodeficiency virus type 1 quasispecies in sequential blood samples and various organs obtained at autopsy. J Virol 1998;72(1):488-496.
40. Olivieri K, Scoggins RM, Bor YC, et al.: The envelope gene is a cytopathic determinant of CCR5 tropic HIV-1. Virology 2007;358(1):23-38.
41. 3. J Infect Dis 2005;192(10):1787-1793.
42. Nabatov A, Pollakis G, Linnemann T, Kliphius A, Chalaby MIM, and Paxton WA: Intrapatient alterations in the human immunodeficiency virus type 1 gp120 V1V2 and V3 regions differentially modulate coreceptor usage, virus inhibition by CC/CXC chemokines, soluble CD4, and the b12 and 2G12 monoclonal antibodies. J Virol 2004;78(1):524-530.
43. Bagnerelli P, Fiorelli L, Vecchi M, Monachetti A, Menzo S, and Clementi M: Analysis of the functional relationship between V3 loop and gp120 context with regard to human immunodeficiency virus coreceptor usage using naturally selected sequences and different viral backbones. Virology 2003;307(2):328-340.
44. Resch W, Hoffman N, and Swanstrom R: Improved success of phenotype prediction of the human immunodeficiency virus type 1 from envelope variable loop 3 sequence using neural networks. Virology 2001;288(1):51-62.
45. Delobel P, Nugeyre MT, Cazabat M, et al.: Population-based sequencing of the V3 region of env for predicting the coreceptor usage of human immunodeficiency virus type 1 quasispecies. J Clin Microbiol 2007;45(5):1572-1580.
46. Etemad-Moghadam B, Sun Y, Nicholson EK, et al.: Envelope glycoprotein determinants of increased fusogenicity in a pathogenic simian-human immunodeficiency virus (SHIV-KB9) passaged in vivo. J Virol 2000;74(9):4433-4440.
47. Westermark B, Ponten J, and Hugosson R: Determinants for the establishment of permanent tissue culture lines from human gliomas. Acta Pathol Microbiol Scand [A] 1973;81(6):791-805.
48. Marmor M, Hertzmark K, Thomas SM, Halkitis PN, and Vogler M: Resistance to HIV infection. J Urban Health 2006;83(1):5-17.
49. Chabot DJ, Chen H, Dimitrov DS, and Broder CC: N-linked glycosylation of CXCR4 masks coreceptor function for CCR5-dependent human immunodeficiency virus type 1 isolates. J Virol 2000;74(9):4404-4413.
50. Coakley E, Petropoulos CJ, and Whitcomb JM: Assessing chemokine co-receptor usage in HIV. Curr Opin Infect Dis 2005;18(1):9-15.